Researchers exploring prostate cancer genomes have discovered that DNA damage comes predominantly from inside the cell rather than from external environmental agents like tobacco or sunlight. Meanwhile, new genetic risk score analyses show that lifestyle factors such as body mass index and smoking status significantly shape how effectively genetic predictions identify high-risk men.
Scientists investigating the genetic underpinnings of prostate cancer have uncovered a surprising absence of external mutational signatures across nearly a thousand genomes. While researchers have long mapped how lifestyle exposures leave distinct marks on DNA in lung or skin cancers, genomic profiles of prostate tumors reveal a very different internal dynamic at play, according to findings discussed by international research groups.
Internal Cellular Damage Overrides External Environmental Marks in Genomes
The realization emerged during a detailed genomic analysis that examined nearly a thousand genomes to trace how external hazards influence cellular health. Investigators expected to find clear genetic footprints left by environmental exposures, but the data pointed elsewhere.
Researchers emphasized that these genomic results do not render lifestyle or environment irrelevant. Factors such as diet, weight, and inflammation can all influence whether prostate cancer develops without leaving direct structural traces in the DNA sequence itself. Instead, the analysis highlighted specific faulty intracellular processes that increase the likelihood of cancer spreading.
Mapping Biological Processes and Preparing for Clinical Validation
By mapping the biological processes that drive tumor behavior, scientists identified patterns that held true even after adjusting for patient age, tumor stage, and pathological grade. One active biological process was even linked to a small cohort of 25 patients who demonstrated a stronger response to a specific type of therapy, though that observation was evaluated retrospectively rather than through a dedicated clinical trial.
Translating these genomic maps into bedside utility remains a distant prospect requiring rigorous validation. Investigators noted that the findings have to be confirmed in other groups of patients before entering standard hospital workflows. The measurement must evolve into a standardized test that produces consistent results, followed by trials involving men actively making treatment decisions.
“It is not going to change how any man is treated tomorrow. But it runs on the kind of DNA sequencing that several health systems already carry out for cancer patients. What we are proposing is to read existing data differently, not to build a new test from scratch.”
Joachim Weischenfeldt, professor at the Biotech Research and Innovation Centre of the University of Copenhagen and Rigshospitalet
Polygenic Risk Scores and the Impact of Age and Smoking
Parallel genetic evaluations are examining how polygenic risk scores (PRS) perform across diverse populations and demographic groups. Roughly 10 percent of the population falls into a high-PRS category, whereas only about 0.2 percent carry rare BRCA2 variants, indicating that a validated PRS can flag a much broader share of high-risk individuals for earlier or more intensive screening.
Performance of the PRS varies significantly depending on age and behavioral history. The score was most predictive in younger men, with predictive strength declining as patients age—aligning with the principle that genetic factors drive risk more forcefully early in life before environmental exposures accumulate. Smoking status introduced another layer of variation, with the PRS performing most strongly in never-smokers and former smokers compared to current smokers.
Body Mass Index, Screening Biases, and Clinical Outcomes
Body mass index presented a counterintuitive trend that challenged conventional expectations about environmental exposure. While genetic risk scores typically perform better when environmental interference is lower, men with higher BMI actually showed stronger PRS associations than those with normal weight.
Researchers suggest this unexpected pattern points directly to screening and detection challenges. Higher BMI is associated with lower circulating prostate-specific antigen (PSA) levels and reduced sensitivity in physical examinations, which often delays detection until the disease advances. A robust genetic score could help improve risk stratification in populations where traditional screening methods prove less effective.
Furthermore, broader clinical association testing using All of Us data confirmed that the prostate cancer PRS links specifically to disease-related outcomes—such as elevated PSA, treatment side effects like urinary incontinence and erectile dysfunction, and bone metastasis—while showing no significant association with unrelated malignancies like breast cancer.
Translating Genomic Research Into Screening Strategies
Future investigations will focus on integrating genetic risk scores with behavioral and clinical factors to refine screening protocols. Researchers emphasize that the immediate priority involves evaluating the practical clinical utility of PRS in real-world healthcare settings and validating predictive markers across independent patient cohorts before clinical implementation moves forward.
